Zhi-xiu X. Lin

Sar, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma.

Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: February 20, 2026

Corrigendum to "Sub-chronic toxicity of the active fraction of a modified Huang-Lian-Jie-Du Decoction" [Toxicol. Rep. 13 (2024) 101682].

Corrigendum to "Sub-chronic toxicity of the active fraction of a modified Huang-Lian-Jie-Du Decoction" [Toxicol. Rep. 13 (2024) 101682].

Journal: Toxicology reports

Published: February 03, 2025

Protective effects of Prunella vulgaris polysaccharides against herpes simplex virus type 1 infection through the STING-TBK1-IRF3 pathway.

Protective effects of Prunella vulgaris polysaccharides against herpes simplex virus type 1 infection through the STING-TBK1-IRF3 pathway.

Journal: Journal of integrative medicine

Published: November 25, 2024

20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters.

20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters.

Journal: Journal of advanced research

Published: May 10, 2024

Sub-chronic toxicity of the active fraction of a modified Huang-Lian-Jie-Du Decoction.

Sub-chronic toxicity of the active fraction of a modified Huang-Lian-Jie-Du Decoction.

Journal: Toxicology reports

Published: April 28, 2024

Assessing the efficacy and safety of Yinqiao powder-maxing Ganshi decoction in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine-study protocol for a randomized, double-blind, placebo-controlled trial.

Assessing the efficacy and safety of Yinqiao powder-maxing Ganshi decoction in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine-study protocol for a randomized, double-blind, placebo-controlled trial.

Journal: Frontiers in pharmacology

Published: July 19, 2023

Corrigendum: A Chinese medicine formula (Bushen Huoxue Tongluo) for the treatment of chronic subjective tinnitus: a study protocol for a pilot, assessor-blinded, randomized clinical trial.

Corrigendum: A Chinese medicine formula (Bushen Huoxue Tongluo) for the treatment of chronic subjective tinnitus: a study protocol for a pilot, assessor-blinded, randomized clinical trial.

Journal: Frontiers in pharmacology

Published: July 14, 2023

Persistent clinical symptoms and their association with CM syndromes in post-COVID-19 rehabilitation patients in Hong Kong.

Persistent clinical symptoms and their association with CM syndromes in post-COVID-19 rehabilitation patients in Hong Kong.

Journal: Heliyon

Published: April 28, 2023

Autophagy Regulators in Cancer.

Autophagy Regulators in Cancer.

Journal: International journal of molecular sciences

Published: April 25, 2023

Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease.

Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease.

Journal: Journal of pharmaceutical analysis

Published: March 26, 2023

Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.

Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.

Journal: Advanced biology

Published: February 07, 2023

Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment.

Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment.

Journal: International journal of biological sciences

Published: January 05, 2023

Showing 1-12 of 95

Last Updated: 09/26/2026